<DOC>
	<DOC>NCT01081327</DOC>
	<brief_summary>Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.</brief_summary>
	<brief_title>Warfarin - How Good Are we at Maintaining Target Range ?</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Prescription for Warfarin Atrial Fibrillation Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma. Conditions with increased risk of bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Safety</keyword>
</DOC>